Send to

Choose Destination
Expert Rev Vaccines. 2016 Dec;15(12):1575-1582. Epub 2016 Jul 6.

Manufacturing DTaP-based combination vaccines: industrial challenges around essential public health tools.

Author information

a Medical Affairs , Sanofi Pasteur , Lyon , France.
b Medical Affairs , Sanofi Pasteur MSD , Lyon , France.


The manufacture of DTP-backboned combination vaccines is complex, and vaccine quality is evaluated by both batch composition and conformance of manufacturing history. Since their first availability, both the manufacturing regulations for DTP combination vaccines and their demand have evolved significantly. This has resulted in a constant need to modify manufacturing and quality control processes. Areas covered: Regulations that govern the manufacture of complex vaccines can be inconsistent between countries and need to be aligned with the regulatory requirements that apply in all countries of distribution. Changes in product mix and quantities can lead to uncertainty in vaccine supply maintenance. These problems are discussed in the context of the importance of these products as essential public health tools. Expert commentary: Increasing demand for complex vaccines globally has led to problems in supply due to intrinsically complex manufacturing and regulatory procedures. Vaccine manufacturers are fully engaged in the resolution of these challenges, but currently changes in demand need ideally to be anticipated approximately 3 years in advance due to long production cycle times.


DTaP combination; compliance; formulation; manufacturing; quality control; supply

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center